अApnaFunda
Menu

ASTRAZENECA PHARMA INDIA LTD (ASTRAZEN)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.72 / 100
Profitability 53Growth 79Balance sheet 84
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.38 / 100
Price 15Earnings 17FII/DII 81

Passes these screensQuality CompounderDebt-light & profitableConsistent compounders

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹6,514.5 latest close · −21.6% over the last 90 sessions

₹6,000₹7,000₹8,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹6,000₹7,000₹8,000Jul 3Sep 4Nov 9

₹6,514.5 month-end · −27.8% over 12 months

₹6,000₹7,000₹8,000₹9,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹6,000₹7,000₹8,000₹9,000Nov '25May '26Nov '26

₹6,514.5 month-end · +36.7% over 3 years

₹6,000₹8,000₹10,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹6,000₹8,000₹10,000Nov '23May '25Nov '26

₹6,514.5 month-end · +306.7% since Jan '19

₹2,500₹5,000₹7,500₹10,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹2,500₹5,000₹7,500₹10,000Jan '19Dec '22Nov '26

52-week range ₹5640.00 to ₹9830.00 · 1-year volatility 22.4%

Was the rally earned?

-28%share price, 1 yearMultiple-driven

Mostly the multiple.

  • Most of the fall came from investors paying a lower multiple (P/E 123.0x to 96.0x); per-share earnings took off 7 points.
  • The share count barely moved.
Net profit growth: −6 pts. Points of the price return explained by net profit growing (or shrinking).−6 ptsNet profit growthP/E change: −21 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−21 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: −28%−28%Share priceNet profit growth: −6 pts. Points of the price return explained by net profit growing (or shrinking).−6ProfitP/E change: −21 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−21P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: −28%−28%Share price
Net profit growth-6 ptsNet profit fell about 7%, which lowers the price.
P/E change-21 ptsThe P/E fell from 123.0x to 96.0x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+37%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 63 points, but investors now pay less per rupee of profit (P/E 120.0x to 96.0x), which took 26 points back.
  • The share count barely moved.
Net profit growth: +63 pts. Points of the price return explained by net profit growing (or shrinking).+63 ptsNet profit growthP/E change: −26 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−26 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +37%+37%Share priceNet profit growth: +63 pts. Points of the price return explained by net profit growing (or shrinking).+63ProfitP/E change: −26 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−26P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +37%+37%Share price
Net profit growth+63 ptsNet profit rose about 71%, which lifts the price.
P/E change-26 ptsThe P/E fell from 120.0x to 96.0x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+108%share price, 5 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 88 points to the rise, while the multiple moved less (P/E 84.1x to 96.0x).
  • The share count barely moved.
Net profit growth: +89 pts. Points of the price return explained by net profit growing (or shrinking).+89 ptsNet profit growthP/E change: +20 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+20 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +108%+108%Share priceNet profit growth: +89 pts. Points of the price return explained by net profit growing (or shrinking).+89ProfitP/E change: +20 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+20P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +108%+108%Share price
Net profit growth+89 ptsNet profit rose about 82%, which lifts the price.
P/E change+20 ptsThe P/E rose from 84.1x to 96.0x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-47.3%recovered 2023-10
1-year volatility22.4%annualised
Beta vs sector index0.683-year daily, correlation 0.27
Volume spikes7last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%2020202120222023202420252026−46.0% 0%−20%−40%2020202220242026−46.0%
Largest drawdowns

-47.3% (2021-01 peak to 2022-05 low, recovered 2023-10)

-45.6% (2025-06 peak to 2026-10 low, not yet recovered)

-33.8% (2019-12 peak to 2020-03 low, recovered 2020-04)

Most recent volume spikes

2026-11-06: 10.1x the 50-day median, price +1.3% that day

2026-10-13: 7x the 50-day median, price -0.7% that day

2026-09-30: 10.2x the 50-day median, price -1.1% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

96.0xP/E todayNear its historic low
Against its own history19th percentile
CheapestMedian 122.9xDearest

Usual range 85.0x to 197.4x since 2019-01.

Against Health Technology96.0x vs 37.0x
This company
96.0x
Sector median
37.0x

159% above the Health Technology median.

16.7x87.0x157.3x227.6xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x87.0x157.3x227.6xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE88th▼ 7 pts vs a year ago
  • Op. margin19th▼ 23 pts vs a year ago
  • Revenue growth82nd▼ 10 pts vs a year ago
  • EPS growth30th▼ 61 pts vs a year ago
  • Debt/equity ↓64th▼ 11 pts vs a year ago
  • Cash cycle ↓73rdflat vs a year ago
  • P/E ↓11th▲ 4 pts vs a year ago
  • 12M momentum8th▼ 87 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~37%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 130.2x, a holder earning 12%/yr needs earnings to grow about 37.3%/yr for 10 years, then trade at 15x.

Delivered24.6%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+12.8 ptsimplied minus delivered
Rank262ndmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%118%236% Jan 2019Nov 2026 0%118%236% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x38.9%40.2%41.4%
15x36.1%37.3%38.6%
20x32.5%33.7%34.9%

Drag a slider to test other assumptions

Implied: 37.3%/yr

Looking back

  • Jan 2020Price implied 55%/yr; EPS has since grown 20%/yr (7.0 yrs)
  • Jan 2021Price implied 49%/yr; EPS has since grown 17%/yr (6.0 yrs)
  • Jan 2022Price implied 39%/yr; EPS has since grown 15%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹6514.50
P/E
96.0x
ROCE
29.0%
Market Cap
₹16287 cr
Revenue (TTM)
₹2433 cr
P/S
6.7x
P/B
18.7x
ROE
19.4%
Operating Margin
7.0%
Debt / Equity
0.1x
Promoter Holding
75.0%
12M Momentum
-27.8%

52-week range

₹5640.00₹9830.00
21% of the way from its 52-week low to its high

Price risk

1Y volatility
22.4%
Beta vs sector
1-year daily
0.57

Balance sheet & cash

Interest cover
operating profit ÷ interest
39.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.17x
low
Share count, 1Y
unchanged

Are profits backed by cash?

5 of 7checks within range1 beyond a threshold
Other income reliance10%Within range

Other income as a share of pre-tax profit (trailing twelve months): 9.6%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 25.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.17xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.17x (cash from operations ₹78 cr, net profit ₹466 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-5 daysWithin range

Debtor days are below the median of the previous three fiscal years by 5 days (34 vs 39). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress0% of fixed assetsWithin range

Capital work-in-progress is 0% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+86 days / 2 yrsNear threshold

Days payable changed by +86 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, DIIs added 3.7 pts.
  • The number of shareholders fell from 32,380 to 29,338 (-9%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters75.0%75.0%0.0 pts
FIIs2.7%2.7%0.0 pts
DIIs2.4%6.1%+3.7 pts
Public and others19.9%16.2%-3.7 pts

Number of shareholders

29,338shareholders-9% since Sep '23
27k30k32k34k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 32,380
Dec '23: 29,032
Mar '24: 29,418
Jun '24: 27,169
Sep '24: 27,615
Dec '24: 27,322
Mar '25: 32,466
Jun '25: 34,378
Sep '25: 32,914
Dec '25: 31,551
Mar '26: 29,007
Jun '26: 29,338
 27k30k32k34k Sep '23Sep '24Sep '25Jun '26
Sep '23: 32,380
Dec '23: 29,032
Mar '24: 29,418
Jun '24: 27,169
Sep '24: 27,615
Dec '24: 27,322
Mar '25: 32,466
Jun '25: 34,378
Sep '25: 32,914
Dec '25: 31,551
Mar '26: 29,007
Jun '26: 29,338

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−6.4%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like ASTRAZENECA PHARMA INDIA LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −20% to +5% vs the market, against +3% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −8.9%, 80% range −13.3% to −6.5%), but the matches cluster in only 5 distinct 12-month windows.

Where the 50 outcomes landed

−60%−40%−20%0%+20%+40%+60%+80%
TASTYBITE · May 2021: −43.8% vs market
METROPOLIS · Sep 2021: −42.6% vs market
TATVA · Dec 2022: −41.4% vs market
NAVINFLUOR · Jul 2023: −39.6% vs market
HAPPSTMNDS · Apr 2023: −33.0% vs market
SYMPHONY · Sep 2020: −31.1% vs market
LALPATHLAB · Oct 2021: −29.6% vs market
VINATIORGA · Jun 2023: −28.9% vs market
SONACOMS · Jun 2024: −26.5% vs market
IPCALAB · Apr 2021: −22.3% vs market
ASIANPAINT · Jan 2023: −22.0% vs market
EMAMILTD · Dec 2021: −21.0% vs market
GRINDWELL · Sep 2023: −20.3% vs market
HONAUT · Aug 2024: −17.6% vs market
VGUARD · Jul 2021: −15.6% vs market
BERGEPAINT · Feb 2021: −15.4% vs market
BRITANNIA · Feb 2021: −15.1% vs market
GODREJCP · Jun 2021: −13.0% vs market
KPITTECH · May 2024: −12.7% vs market
LTTS · Jun 2024: −12.2% vs market
DMART · Jan 2024: −10.6% vs market
3MINDIA · Dec 2020: −9.8% vs market
SYNGENE · May 2021: −9.3% vs market
CROMPTON · Feb 2021: −7.3% vs market
VOLTAS · May 2021: −6.5% vs market
CENTURYPLY · Feb 2023: −6.3% vs market
TTKPRESTIG · Jul 2021: −5.6% vs market
PIIND · Feb 2021: −5.5% vs market
BATAINDIA · Oct 2020: −5.5% vs market
UBL · Jul 2020: −4.2% vs market
GARFIBRES · Apr 2022: −3.0% vs market
ORIENTELEC · Apr 2021: −1.2% vs market
RELAXO · Apr 2021: −0.1% vs market
ALKEM · Feb 2021: +0.3% vs market
MARICO · Jan 2022: +3.9% vs market
DABUR · Jan 2022: +4.6% vs market
PIDILITIND · Jan 2024: +4.9% vs market
AFFLE · Oct 2023: +4.9% vs market
ABBOTINDIA · Dec 2021: +5.8% vs market
KAJARIACER · Oct 2022: +6.3% vs market
SFL · Sep 2020: +7.7% vs market
PAGEIND · Oct 2020: +17.4% vs market
POLYMED · Feb 2022: +18.5% vs market
SUMICHEM · Mar 2021: +24.9% vs market
ASTRAL · May 2022: +28.3% vs market
MAPMYINDIA · Jun 2023: +30.3% vs market
HAVELLS · Jan 2020: +45.6% vs market
TITAN · Feb 2021: +50.8% vs market
PERSISTENT · May 2024: +57.3% vs market
FINEORG · Aug 2021: +102.9% vs market
Similar setups −6.4%All companies +2.5%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−6.4%
All companies' median
+2.5%
Beat the market
34% vs 53%

50 past situations · 50 companies · 32 months · 2020–2024

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
BERGEPAINT
Process Industries		 Feb 2021 101x28% +20%−16% −15%
RELAXO
Consumer Non-Durables		 Apr 2021 96x24% +38%−8% 0%
GRINDWELL
Process Industries		 Sep 2023 64x28% +1%−15% −20%
UBL
Consumer Non-Durables		 Jul 2020 59x17% −33%−33% −4%
ABBOTINDIA
Health Technology		 Dec 2021 59x35% +24%−16% +6%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
ASTRAL
Producer Manufacturing		 May 2022 86x29% −8%−30% +28%
VGUARD
Producer Manufacturing		 Jul 2021 53x26% +53%−11% −16%
EMAMILTD
Consumer Non-Durables		 Dec 2021 51x29% +23%−15% −21%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, P/S and drawdown from 12-month high. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ASTRAZENECA PHARMA INDIA LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

BIKAJI FOODS INTBIKAJI
Consumer Non-Durables
65%similar
volatilityEPS growth
DOMS INDUSTRIESDOMS
Producer Manufacturing
54%similar
revenuedebt/equity
AVENUE SUPERMARTS LTD DMARTDMART
Retail Trade
53%similar
volatilityoperating margin
ENDURANCE TECHNOLOGIESENDURANCE
Producer Manufacturing
53%similar
promoter holdingdebt/equity
MOTHERSON SUMI WIRING INDMSUMI
Producer Manufacturing
50%similar
debt/equityoperating margin
AKUMS DRUGS AND PHARMAAKUMS
Health Technology
34%similar
promoter holdingmarket cap
INDEGENEINDGN
Health Technology
33%similar
market capvolatility
AJANTA PHARMAAJANTPHARM
Health Technology
32%similar
volatilityROCE

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Dec '23

  1. NovPriceVolume reached 10.1x its 50-day median on 2026-11-06; price +1.3% that day.
  2. OctPriceFell 46% from the Jun 2025 peak to the Oct 2026 low.
  3. SepResultsYear-on-year EPS growth turned negative.
  4. SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
  5. JulPriceVolume reached 24.8x its 50-day median on 2026-07-31; price +0.1% that day.
  6. JunPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  7. MayPriceVolume reached 13.7x its 50-day median on 2026-05-27; price -3.5% that day.
  8. MarPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
Show 22 earlier events
  1. MarPriceVolume reached 12.1x its 50-day median on 2026-03-27; price -5.8% that day.
  2. DecPriceVolume reached 9.4x its 50-day median on 2025-12-30; price -1.4% that day.
  3. SepResultsYear-on-year EPS growth turned positive.
  4. SepPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  5. AugPriceVolume reached 8.1x its 50-day median on 2025-08-14; price -1.2% that day.
  6. JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
  7. JunPriceVolume reached 66.9x its 50-day median on 2025-06-02; price +17.1% that day.
  8. MarPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  9. MarPriceVolume reached 18.4x its 50-day median on 2025-03-20; price +6.1% that day.
  10. DecPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
  11. OctPriceVolume reached 96.8x its 50-day median on 2024-10-07; price +5.5% that day.
  12. SepResultsYear-on-year EPS growth turned negative.
  13. SepValuationP/E crossed above the 90th percentile of its own history to date (207.9x).
  14. SepPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
  15. SepPriceVolume reached 166.1x its 50-day median on 2024-09-24; price +16.7% that day.
  16. JulPriceRegained the 2024-02 peak, 4 months after the low.
  17. JunResultsRevenue (TTM) reached a new high of ₹1,295 cr.
  18. MayPriceVolume reached 16.9x its 50-day median on 2024-05-27; price +6.8% that day.
  19. MarPriceFell 29% from the Feb 2024 peak to the Mar 2024 low.
  20. JanValuationP/E crossed above the 90th percentile of its own history to date (166.6x).
  21. JanPriceVolume reached 41.4x its 50-day median on 2024-01-10; price +17.5% that day.
  22. DecPriceVolume reached 62.1x its 50-day median on 2023-12-22; price +12.6% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1196.0x₹2433 cr19.4%29.0%0.1x
2026-1093.8x₹2433 cr19.5%29.0%0.1x
2026-0991.2x₹2433 cr19.5%29.0%0.1x
2026-0892.7x₹2276 cr21.5%29.0%0.1x
2026-07108.0x₹2276 cr21.5%29.0%0.1x
2026-06109.7x₹2276 cr21.5%29.0%0.1x
2026-05107.4x₹2177 cr26.1%33.0%0.0x
2026-04102.2x₹2177 cr26.1%33.0%0.0x
2026-0396.6x₹2177 cr26.1%33.0%0.0x
2026-02111.1x₹2005 cr25.8%33.0%0.0x
2026-01107.3x₹2005 cr25.8%33.0%0.0x
2025-12113.3x₹2005 cr25.8%33.0%0.0x
2025-11123.0x₹1854 cr23.8%33.0%0.0x
2025-10130.3x₹1854 cr23.8%33.0%0.0x
2025-09124.2x₹1854 cr23.8%33.0%0.0x
2025-08182.8x₹1716 cr14.9%33.0%0.0x
2025-07198.4x₹1716 cr14.9%33.0%0.0x
2025-06192.4x₹1716 cr14.9%33.0%0.0x
2025-05205.6x₹1619 cr13.5%31.0%0.0x
2025-04223.9x₹1619 cr13.5%31.0%0.0x
2025-03222.0x₹1619 cr13.5%31.0%0.0x
2025-02204.5x₹1485 cr11.4%31.0%0.0x
2025-01220.9x₹1485 cr11.4%31.0%0.0x
2024-12223.0x₹1485 cr11.4%31.0%0.0x
2024-11171.2x₹1388 cr13.3%31.0%0.0x
2024-10198.9x₹1388 cr13.3%31.0%0.0x
2024-09207.9x₹1388 cr13.3%31.0%0.0x
2024-08102.0x₹1295 cr22.6%31.0%0.0x
2024-07108.9x₹1295 cr22.6%31.0%0.0x
2024-0696.8x₹1295 cr22.6%31.0%0.0x
2024-05155.6x₹1003 cr16.8%31.0%0.0x
2024-04134.3x₹1003 cr16.8%31.0%0.0x
2024-03134.2x₹1003 cr16.8%31.0%0.0x
2024-02138.9x₹1003 cr16.8%31.0%0.0x
2024-01166.6x₹1003 cr16.8%31.0%0.0x
2023-12139.1x₹1003 cr16.8%31.0%0.0x
2023-11120.0x₹1003 cr16.8%31.0%0.0x
2023-10117.7x₹1003 cr16.8%31.0%0.0x
2023-09113.4x₹1003 cr16.8%31.0%0.0x
2023-08107.2x₹1003 cr16.8%31.0%0.0x
2023-0797.3x₹1003 cr16.8%31.0%0.0x
2023-0693.3x₹1003 cr16.8%31.0%0.0x
2023-05144.6x₹806 cr12.1%16.0%0.0x
2023-04129.4x₹806 cr12.1%16.0%0.0x
2023-03132.0x₹806 cr12.1%16.0%0.0x
2023-02135.7x₹806 cr12.1%16.0%0.0x
2023-01136.4x₹806 cr12.1%16.0%0.0x
2022-12133.8x₹806 cr12.1%16.0%0.0x
2022-11136.9x₹806 cr12.1%16.0%0.0x
2022-10133.9x₹806 cr12.1%16.0%0.0x
2022-09126.3x₹806 cr12.1%16.0%0.0x
2022-08124.8x₹806 cr12.1%16.0%0.0x
2022-07124.4x₹806 cr12.1%16.0%0.0x
2022-06109.8x₹806 cr12.1%16.0%0.0x
2022-0580.6x₹814 cr20.4%30.0%0.0x
2022-0473.7x₹814 cr20.4%30.0%0.0x
2022-0368.4x₹814 cr20.4%30.0%0.0x
2022-0269.9x₹814 cr20.4%30.0%0.0x
2022-0174.9x₹814 cr20.4%30.0%0.0x
2021-1283.0x₹814 cr20.4%30.0%0.0x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback